NYSE: LLYEli Lilly & Co Stock
$898.95+13.75 (+1.55%)
Updated Apr 30, 2025
LLY Price
$898.95
Fair Value Price
N/A
Market Cap
$852.36B
52 Week Low
$677.09
52 Week High
$972.53
P/E
76.44x
P/B
60.06x
P/S
15.44x
PEG
1.53x
Dividend Yield
0.43%
Revenue
$45.04B
Earnings
$10.59B
Gross Margin
81.3%
Operating Margin
28.15%
Profit Margin
23.5%
Debt to Equity
4.54
Operating Cash Flow
$9B
Beta
0.59
Next Earnings
May 1, 2025
Ex-Dividend
N/A
Next Dividend
N/A
LLY Overview
Eli Lilly and Company offers medicines for cardiovascular conditions, diabetes, endocrinology, cancer, neurological problems, immune disorders, men's health, and musculoskeletal problems. Eli Lilly was founded in 1876 and is headquartered in Indianapolis, IN.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine LLY's potential to beat the market
BBuy
- Stocks with a Zen Rating of Buy (B) had an average return of +19.88% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: General Drug Manufacturer
Industry Rating
A
LLY
Ranked#8 of 18
Ranked#8 of 18
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $156.31 | A | |
| $106.54 | A | |
| $50.20 | A |
Be the first to know about important LLY news, forecast changes, insider trades & much more!
LLY News
Overview
Due Diligence Score
–
Industry Average (40)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how LLY scored across 38 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
LLY ($898.95) is trading above its intrinsic value of $276.60, according to an updated version of Benjamin Graham's Formula from Chapter 11 of "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
LLY is poor value based on its earnings relative to its share price (76.44x), compared to the US market average (29.18x)
P/E vs Market Valuation
LLY is poor value based... subscribe to Premium to read more.
P/E vs Industry Valuation
There are 35 more LLY due diligence checks available for Premium users.
Valuation
LLY price to earnings (PE)
For valuing profitable companies with steady earnings
Company
76.44x
Industry
54.95x
Market
29.18x
LLY is poor value based... subscribe to Premium to read more.
P/E vs Industry Valuation
LLY is poor value based... subscribe to Premium to read more.
P/E vs Market Valuation
LLY price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
60.06x
Industry
6.33x
LLY is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
LLY price to earnings growth (PEG)
For valuing profitable companies with growth potential
LLY is poor value relative... subscribe to Premium to read more.
PEG Value Valuation
LLY's financial health
Profit margin
Revenue
$13.5B
Net Income
$4.4B
Profit Margin
32.6%
LLY's Earnings (EBIT) of $12.68B... subscribe to Premium to read more.
Interest Coverage Financials
LLY's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$78.7B
Liabilities
$64.4B
Debt to equity
4.54
LLY's short-term assets ($32.74B) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
LLY's long-term liabilities ($36.07B) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
LLY's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
LLY's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$2.5B
Investing
-$1.9B
Financing
-$225.4M
LLY's operating cash flow ($8.82B)... subscribe to Premium to read more.
Debt Coverage Financials
LLY vs General Drug Manufacturer Stocks
Eli Lilly & Co Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.